Skip to main content
SpringerLink
Log in

Gastrointestinal Stromal Tumors: Surgical and Medical Therapy

  • Chapter
What’s New in Surgical Oncology

Abstract

Gastrointestinal stromal tumors (GISTs) are rare neoplasms, with an estimated incidence of 14.2 cases/million/year in northen Italy [1]. However, they are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mucciarini C, Rossi G, Bertolini F, et al (2007) Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 7: 230

    Article  PubMed  Google Scholar 

  2. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130: 1466–1478

    PubMed  CAS  Google Scholar 

  3. Roberts PJ, Eisenberg B (2002) Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 38: S37–S38

    Article  PubMed  Google Scholar 

  4. Fletcher CD, Berman JJ, Corless C, et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459–465

    Article  PubMed  Google Scholar 

  5. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70–83

    Article  PubMed  Google Scholar 

  6. Demetri GD, von Mehren M, Blanke CD, et al (2002) Efficacy and safety of imatinibmesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472–480

    Article  PubMed  CAS  Google Scholar 

  7. Blackstein ME, Blay JY, Corless C, et al (2006) Gastrointestinal stromal tumors: consensus statement on diagnosis and treatment. Can J Gastroenterol 20: 157–163

    PubMed  Google Scholar 

  8. Casali PG, Blay J-Y (2010) Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: v98–v102

    Article  PubMed  Google Scholar 

  9. Agaimy A, Hartmann A (2010) Hereditary and non-hereditary syndromic gastrointestinal stromal tumors. Pathologe 31: 430–437

    Article  PubMed  CAS  Google Scholar 

  10. Demetri GD, von Mehren M, Antonescu C et al (2010) NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cane Netw 8: S1–41

    CAS  Google Scholar 

  11. Bonvalot S, Eldweny H, Pechoux CL et al (2006) Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 13: 1596–1603

    Article  PubMed  CAS  Google Scholar 

  12. DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: 51–58

    Article  PubMed  CAS  Google Scholar 

  13. Jeong IH, Kim JH, Lee SR et al (2012) Minimally invasive treatment of gastric gastrointestinal stromal tumors: laparoscopic and endoscopic approach. Surg Laparosc Endosc Percutan Tech 22: 244–50

    Article  PubMed  Google Scholar 

  14. Novitsky YW, MD, Kercher KW, Sing RF et al (2006) Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg 243: 738–747

    Article  PubMed  Google Scholar 

  15. Nishimura J, Nakajima K, Omori T et al (2007) Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs open resection. Surg Endosc 21: 875–878

    Article  PubMed  Google Scholar 

  16. Pucci MJ, Berger AC, Lim PW, et al (2012) Laparoscopic approaches to gastric gastrointestinal stromal tumors: an institutional review of 57 cases. Surg Endosc 26: 3509–3514

    Article  PubMed  Google Scholar 

  17. Furukawa M, Izumi S, Asano H et al (2012) Late umbilical port-site recurrence of a gastrointestinal stromal tumor with an acquired PDGFRα mutation after laparoscopic resection: report of a case. Surg Laparosc Endosc Percutan Tech 22: e109–111

    Article  PubMed  Google Scholar 

  18. Blay JY, Bonvalot S, Casali P et al (2005) Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 16: 566–578

    Article  PubMed  Google Scholar 

  19. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. Lancet 364: 1127–1134

    Article  PubMed  CAS  Google Scholar 

  20. Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard-versus high-dose imatinibmesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26: 620–625

    Article  PubMed  CAS  Google Scholar 

  21. Van Glabbeke M, Verweij J, Casali PG et al (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer — Italian Sarcoma Group — Australian Gastrointestinal Trials Group Study. J Clin Oncol 23: 5795–5804

    Article  PubMed  Google Scholar 

  22. Mussi C, Ronellenfitsch U, Jacob J et al (2009) Post-imatinib surgery in advanced/metastatic GIST. Is it worthwhile in all patients? Ann Oncol 21: 403–408

    Article  PubMed  Google Scholar 

  23. Raut CP, Posner M, Desai J et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24: 2325–2331

    Article  PubMed  CAS  Google Scholar 

  24. DeMatteo RP, Maki RG, Singer S et al (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245: 347–352

    Article  PubMed  Google Scholar 

  25. Le Cesne A, van Glabbeke M, Verweij J et al (2009) Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinibmesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 20: 3969–3974

    Article  Google Scholar 

  26. Reichardt P, Blay J-Y, von Mehren M (2010) Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther 10: 221–232

    Article  PubMed  Google Scholar 

  27. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutation of c-kit in human gastrointestinal stromal tumors. Science 279: 577–580

    Article  PubMed  CAS  Google Scholar 

  28. VanGlabbeke M, Verweij J, Blay JY et al (2012) Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1640 patients. J Clin Oncol 28: 1247–1253

    Google Scholar 

  29. Corless CL.Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumors: origin and molecular oncology. Nat Rev Cancer 11: 865–878

    PubMed  CAS  Google Scholar 

  30. Dematteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinibmesylate after resection of localised, primary gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. Lancet 373: 1097–1104

    Article  PubMed  CAS  Google Scholar 

  31. Corless CL, Ballman KY, Antonescu C et al (2010) Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST). Results of the Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol 28(suppl; abstr 1006)

    Google Scholar 

  32. Joensuu H, Eriksson M, Sundby Hall K et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307: 1265–1272

    Article  PubMed  CAS  Google Scholar 

  33. Consensus Panel ESMO Guidelines 2012 (2012) Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23: 49–55

    Article  Google Scholar 

  34. Gold JS.Gonen M. Gutierrez A et al (2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumor: a retrospective analysis. Lancet Oncol 10: 1045–1052

    Article  PubMed  Google Scholar 

  35. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. NEJM 344: 1052–1056

    Article  PubMed  CAS  Google Scholar 

  36. Van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib(STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 358: 1421–1423

    Article  PubMed  Google Scholar 

  37. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a metanalysis of 1640 patients. J Clin Oncol 28: 1247–1253

    Article  Google Scholar 

  38. Von Mehren M, Heinrich MC, Joensuu H et al (2011) Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinibmesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). J Clin Oncol 29 (suppl; abstr 10016)

    Google Scholar 

  39. Le Cesne A, Ray-Coquard I, Bui BN et al (2010) Discontinuation of imatinib inpatients with advanced gastrointestinal stromal tumors after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11: 942–949

    Article  PubMed  Google Scholar 

  40. Antonescu CR, Besmer P, Guo T et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation. Clin Cancer Res 11: 4182–4190

    Article  PubMed  CAS  Google Scholar 

  41. Demetri GD, van Oosterom AT, Garrett CR et al (2008) Efficacy and safety of Sunitinibmalate in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomized controlled trial. Lancet 368: 1329–1338

    Article  Google Scholar 

  42. George S, Blay JY, Casali PG et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumors after imatinib failure. Eur J Cancer 45: 1959–1968

    Article  PubMed  CAS  Google Scholar 

  43. Reichardt P, Blay JY, Gelderbrom H et al (2010) Phase III trial of nilotinib inpatients with advanced gastrointestinal stromal tumor (GIST). First results from ERNEST g3. J Clin Oncol 28 (suppl; abstr 10017)

    Google Scholar 

  44. Kindler HL, Campbell K, Wroblewski R et al (2011) Sorafenib (SOR) in patients (pts) with imatinib (EVI) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results od a University of Chicago phase II consortium trial. J Clin Oncol 29: 607s (suppl; abstr 10009)

    Article  Google Scholar 

  45. Demetri GD et al (2012) Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. ASCO 2012 Annual Meeting. J Clin Oncol 30: 2401–2407

    Article  PubMed  Google Scholar 

  46. Fumagalli E, Coco P, Morosi C et al (2010) Sunitinib rechallenge in two advanced GIST patients after third-line anti-tyrosine kinase therapy. J Clin Oncol 28 (suppl; abstr e20519)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology, Careggi Hospital, Florence, Italy

    Silvia Gasperoni & Roberto Manetti

  2. Oncology, Presidio Sanitario Gradenigo, Turin, Italy

    Alessandro Comandone

  3. Emergency Surgery, Careggi Hospital, Florence, Italy

    Pietro Tonelli

Authors
  1. Alessandro Comandone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia Gasperoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Manetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pietro Tonelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandro Comandone .

Editor information

Editors and Affiliations

  1. General, Emergency and Minimally Invasive Surgery, Careggi Hospital, Florence, Italy

    Andrea Valeri , Carlo Bergamini  & Jacopo Martellucci ,  & 

  2. Local Healthcare Unit ULSS 19 - Veneto, Adria, Italy

    Ferdinando Agresta

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Italia

About this chapter

Cite this chapter

Comandone, A., Gasperoni, S., Manetti, R., Tonelli, P. (2013). Gastrointestinal Stromal Tumors: Surgical and Medical Therapy. In: Valeri, A., Bergamini, C., Agresta, F., Martellucci, J. (eds) What’s New in Surgical Oncology. Springer, Milano. https://doi.org/10.1007/978-88-470-5310-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5310-6_8

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5309-0

  • Online ISBN: 978-88-470-5310-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation